Peer-reviewed journal publishes data on Theratechnologies’ HIV drug

The 52-week data of Theratechnologies’ (TSX:TH) second Phase 3 trial evaluating tesamorelin for the treatment of excess abdominal fat in HIV-infected patients with lipodystrophy was published in the latest issue of JAIDS Journal of Acquired Immune Deficiency Syndromes. “We are proud to have data from our Phase 3 clinical program published in another recognized scientific [...]

LOM urges buy on weakness in Theratechnologies

Theratechnologies (TSX:TH) has released new dates for the final FDA review and decision on approval of its drug tesamorelin, which should clear uncertainty surrounding the stock, Loewen, Ondaatje, McCutcheon says in a new report. “Should downward pressure occur in reaction to the delay, we believe this would present investors with a buying opportunity,” writes analyst [...]

FDA procedural delay hits Theratechnologies

The FDA has informed Theratechnologies (TSX:TH) that it plans to reschedule an advisory committee meeting to consider the company’s tesamorelin drug to treat excess abdominal fat in HIV patients. Originally scheduled for Feb. 24, the delay is “entirely procedural and is not related to the tesamorelin new drug application,” the company said in a statement. [...]

In conversation with Maher Yaghi

As Desjardins Securities’ healthcare and biotech analyst for the past five years, Maher Yaghi has gained a wide following with a blunt, tell-it-like-it-is approach to covering a sector that has struggled to win the hearts and minds of investors in recent years.  His early research and “buy” recommendations on Theratechnologies and Paladin Labs established his [...]

« Previous Page